Jim Cramer Says Johnson & Johnson (JNJ) Stock Could Fall to $160 Level
We recently published a list of Jim Cramer’s Latest Stock Moves: Top 10 Calls. In this article, we are going to take a look ...
MassDevice15 小时
Johnson & Johnson Neurovascular has a new worldwide president
Following former J&J MedTech Neurovascular Worldwide President Mark Dickinson’s announcement last week that he was leaving ...
BioSpace6 天
16 Years And 3 Texas Two-Steps Later, J&J’s Talc Lawsuit Awaits Key Ruling
Johnson & Johnson has been fighting thousands of lawsuits over its now-discontinued talc products for 16 years. A pending ...
Courthouse News Service6 天
Johnson & Johnson investors defend class action over reports of asbestos-laden baby powder
Johnson & Johnson claims a federal judge wrongfully granted its investors class certification for losses related to purported ...
Fierce Biotech7 天
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
MassDevice5 天
Johnson & Johnson MedTech wins FDA nod for enhanced robotic-assisted bronchoscopy
Johnson & Johnson MedTech announced today that the FDA cleared its Monarch Quest technology for robotic-assisted bronchoscopy ...
Business Wire12 天
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15 th to review first-quarter results.